STOCK TITAN

Insider at Aura Biosciences (NASDAQ: AURA) files to sell shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Aura Biosciences insider Amy Elazzouzi has filed a Form 144 indicating an intention to sell up to 1,581 shares of the company’s common stock through broker Morgan Stanley Smith Barney LLC on or about 01/20/2026. The filing lists an aggregate market value of $7,683.66 for this planned sale, with 63,503,269 shares of common stock outstanding and the stock listed on Nasdaq.

The securities to be sold were originally acquired as a restricted stock unit award granted on 01/19/2023 under Aura Biosciences’ 2021 Stock Option and Incentive Plan, in an amount of 2,844 shares. Over the past three months, the same seller has sold 896 shares of common stock for gross proceeds of $5,689.60. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about Aura Biosciences.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Aura Biosciences (AURA) Form 144 filing disclose?

The Form 144 shows that Amy Elazzouzi plans to sell up to 1,581 shares of Aura Biosciences common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,683.66, and that the stock is listed on Nasdaq.

How many Aura Biosciences shares are being registered for potential sale?

The notice covers a planned sale of 1,581 shares of Aura Biosciences common stock, with an indicated aggregate market value of $7,683.66.

How were the Aura Biosciences shares to be sold originally acquired?

The shares to be sold come from a restricted stock unit award of 2,844 shares granted on 01/19/2023 under Aura Biosciences’ 2021 Stock Option and Incentive Plan.

What prior Aura Biosciences stock sales by this insider are disclosed?

Over the past three months, the filing reports that Amy Elazzouzi sold 896 shares of Aura Biosciences common stock on 10/29/2025 for gross proceeds of $5,689.60.

How many Aura Biosciences shares are outstanding according to this filing?

The Form 144 states that 63,503,269 shares of Aura Biosciences common stock are outstanding.

What representations does the seller make in this Aura Biosciences Form 144?

By signing the notice, the seller represents that they do not know any material adverse information about Aura Biosciences’ current or prospective operations that has not been publicly disclosed and acknowledges the criminal penalties for intentional misstatements.

Which broker is handling the planned Aura Biosciences share sale?

The planned sale of 1,581 Aura Biosciences common shares is listed as being through Morgan Stanley Smith Barney LLC, with trading on the Nasdaq exchange.
Aura Biosciences, Inc.

NASDAQ:AURA

AURA Rankings

AURA Latest News

AURA Latest SEC Filings

AURA Stock Data

364.51M
57.16M
1.98%
84.55%
4.5%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON